Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1707-1713

  Nishimura, Reiki ^a   Anan, Keisei ^b   Yamamoto, Yutaka ^c   Higaki, Kenji ^d   Tanaka, Maki ^e   Shibuta, Kenji ^f   Sagara, Yasuaki ^g   Ohno, Shinji ^h   Tsuyuki, Shigeru ⁱ   Mase, Takahiro ^j   Teramukai, Satoshi ^k  

^a KUMAMOTO CITY HOSPITAL   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^d HIROSHIMA CITY HOSPITAL   (Japan)

^e Social Insurance Kurume Daiichi Hospital   (Japan)

^f Ueo Breast Surgery Hospital   (Japan)

^g SAGARA HOSPITAL   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ OSAKA RED CROSS HOSPITAL   (Japan)

^j Ichinomiya Municipal Hospital   (Japan)

^k KYOTO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Aromatase inhibitor; Breast cancer; Luteinizing hormone releasing hormone analogue; Premenopausal patient; Tamoxifen

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; ARTHRALGIA; ARTHRITIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FRACTURE; HOT FLUSH; HUMAN; INSOMNIA; LIMB PAIN; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRECORDIAL PAIN; PREMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; SWEATING; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; PREMENOPAUSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 84876239885     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2312     Document Type: Article

References (22)

1. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M and Lisboa B; Zoladex Early Breast Cancer Research Association Study: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the 'Zoladex' Early Breast Cancer Research Association study. J Clin Oncol 20: 4628-4635, 2002. (Pubitemid 36025278)
2. Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M and Sauerbrei W; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group: Survival analyses from the ZEBRA study: goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39: 1711-1717, 2003. (Pubitemid 36897608)
3. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC and Simpson ER: Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 53: 412-417, 1981. (Pubitemid 13250304)
4. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B and Forbes JF: A randomized study to compare the effect of the luteinising hormone releasing hormone (LH-RH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 31A: 137-142, 1995.
5. Forward DP, Cheung KL, Jackson L and Robertson JF: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90: 590-594, 2004. (Pubitemid 38297195)
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
7. Japan Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. 14th edition. Kanehara Publications, Tokyo, 2000 (In Japanese).
8. National Cancer Institute: Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov.
9. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C and Pujade-Lauraine E: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30: 2718-2724, 2012.
10. Smith IE and Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348: 2431-2442, 2003. (Pubitemid 36682823)
11. Smith IE, Dowsett M, Yap YS, Walsh G, Lønning PE, Santen RJ and Hayes D: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24: 2444-2447, 2006. (Pubitemid 46630620)
12. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M and Valero V: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28: 3917-3921, 2010.
13. Michaud JB, Jones KL and Buzdar AU: Combination endocrine therapy in the management of breast cancer. Oncologist 6: 538-546, 2001. (Pubitemid 33152098)
14. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A and von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-3767, 2000.
15. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J and Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26: 4883-4890, 2008.
16. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA and Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001. (Pubitemid 32451796)
17. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R and Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002.
18. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL and Massimini G: Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18: 1399-1411, 2000. (Pubitemid 30205385)
19. Yao S, Xu B, Li Q, Zhang P, Yuan P, Wang J, Ma F and Fan Y: Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocr J 58: 509-516, 2011.
20. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E and Greil R; ABCSG-12 Trial Investigators and Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
21. Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, Luini A, Viale G, Santoro A, Colleoni M and Goldhirsch A: Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 126: 431-441, 2011.
22. Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H and Noguchi S: Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 13: 345-352, 2012.